구조모아 (StructureMoa)항암 chemical structure spider web
방문Alex's Lemonade Stand Foundation
GD2 CAR T cells(Alex's Lemonade Stand Foundation)은 GD2 표적 세포·유전자 치료로, Neuroblastoma 영역에서 개발·상용화 중입니다. 작용기전: CAR-T therapy in ALK-mutant NB primarily by attenuating PD-L1-mediated immune evasion, supporting its potential as a combinatorial therapeutic strateg. Phase 1 안전성·PK 탐색 단계입니다. Disease-specific study endpoint: 122; 170. The purpose of this first in human study is to determine the safety and feasibility of 1RG-CART t. 차별점: novel platform to perform guided CAR insertion into primary human T-cells using nanoplasmid DNA and holds the potential to in.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
GD2
Neuroblastoma
Recruiting
2026-07-13
Data Confidence · Medium
Development Signal · Watch
CAR-T) cell therapy in overcoming immune evasion in ALK-mutant NB
retroviral vector encoding an interleukin-15 transgene alongside the GD2-specific CAR
novel platform to perform guided CAR insertion into primary human T-cells using nanoplasmid DNA and holds the potential to in
CAR-T therapy in ALK-mutant NB primarily by attenuating PD-L1-mediated immune evasion, supporting its potential as a combinatorial therapeutic strateg
T cell activation
apoptosis through p53/caspase-3/PARP signaling pathway
PD-L1) expression
resistance to GD2
구조화 데이터
xenograft model
mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Alex's Lemonade Stand Foundation
GD2 CAR T cells(Alex's Lemonade Stand Foundation)은 GD2 표적 세포·유전자 치료로, Neuroblastoma 영역에서 개발·상용화 중입니다. 작용기전: CAR-T therapy in ALK-mutant NB primarily by attenuating PD-L1-mediated immune evasion, supporting its potential as a combinatorial therapeutic strateg. Phase 1 안전성·PK 탐색 단계입니다. Disease-specific study endpoint: 122; 170. The purpose of this first in human study is to determine the safety and feasibility of 1RG-CART t. 차별점: novel platform to perform guided CAR insertion into primary human T-cells using nanoplasmid DNA and holds the potential to in.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
GD2
Neuroblastoma
Recruiting
2026-07-13
Data Confidence · Medium
Development Signal · Watch
CAR-T) cell therapy in overcoming immune evasion in ALK-mutant NB
retroviral vector encoding an interleukin-15 transgene alongside the GD2-specific CAR
novel platform to perform guided CAR insertion into primary human T-cells using nanoplasmid DNA and holds the potential to in
CAR-T therapy in ALK-mutant NB primarily by attenuating PD-L1-mediated immune evasion, supporting its potential as a combinatorial therapeutic strateg
T cell activation
apoptosis through p53/caspase-3/PARP signaling pathway
PD-L1) expression
resistance to GD2
구조화 데이터
xenograft model
mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.